MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/hc9.0000000000000448

Медицинская библиотека · Hepatology communications · 2024

Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.

Sakane Sadatsugu, Hikita Hayato, Shirai Kumiko, Sakamoto Tatsuya, Narumi Ryohei, Adachi Jun, Kakita Naruyasu, Yamada Yukinori, Toyoda Hidenori, Takahashi Hirokazu, Suda Goki, Kai Machiko, Tahata Yuki, Sakamori Ryotaro, Kumazaki Shusuke, Fukumoto Kenji, Myojin Yuta, Murai Kazuhiro, Kodama Takahiro, Tatsumi Tomohide, Tomonaga Takeshi, Sakamoto Naoya, Morii Eiichi, Takehara Tetsuo

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

There is a need for novel noninvasive markers for metabolic dysfunction-associated steatotic liver disease (MASLD) to stratify patients at high risk for liver-related events including liver cancer and decompensation. In the present study, we used proteomic analysis of proteins in extracellular vesicles (EVs) to identify new biomarkers that change with fibrosis progression and can predict the development of liver-related events.

METHODS

We analyzed serum EVs from 50 patients with MASLD assessed for liver fibrosis by biopsy and identified proteins that altered with advanced fibrosis. A further evaluation was conducted on another cohort of 463 patients with MASLD with biopsy.

RESULTS

Eight candidate proteins were identified by proteomic analysis of serum EVs. Among them, serum levels of Fibulin-3, Fibulin-1, and Ficolin 1 correlated with their EV levels. In addition, serum Fibulin-3 and serum Fibulin-1 levels changed significantly with advanced fibrosis. Using another cohort with biopsy, we found that the serum Fibulin-3 concentration was significantly greater in those with advanced fibrosis but that the serum Fibulin-1 concentration was not significantly different. Multivariate Cox proportional hazards analysis revealed that a higher Fibrosis-4 (FIB-4) index and higher serum Fibulin-3 concentration were independent risk factors for liver-related events. When the cutoff value for the serum Fibulin-3 concentration was 6.0 µg/mL according to the Youden index of AUROCs, patients with high serum Fibulin-3 significantly more frequently developed liver-related events than did other patients. Validation using another cohort of 226 patients with clinically diagnosed MASLD confirmed that high serum Fibulin-3 levels are associated with a greater frequency of liver-related events.

CONCLUSIONS

Serum Fibulin-3 was identified as a biomarker for predicting liver-related events in patients with MASLD.

Для цитирования: Sakane Sadatsugu, Hikita Hayato, Shirai Kumiko, Sakamoto Tatsuya, Narumi Ryohei, Adachi Jun, Kakita Naruyasu, Yamada Yukinori, Toyoda Hidenori, Takahashi Hirokazu, Suda Goki, Kai Machiko, Tahata Yuki, Sakamori Ryotaro, Kumazaki Shusuke, Fukumoto Kenji, Myojin Yuta, Murai Kazuhiro, Kodama Takahiro, Tatsumi Tomohide, Tomonaga Takeshi, Sakamoto Naoya, Morii Eiichi, Takehara Tetsuo. Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.. Hepatology communications. 2024. DOI: 10.1097/hc9.0000000000000448.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.